AbbVie Inc (ABBV)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 50% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- Weekly momentum+5.4% over the past week+6
- 52-week positionPressing 52-week highs+30
- QualityRevenue growing 10% y/y+5
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst here is analyst-driven, with RBC's reiterated Outperform and $280 target plus valuation commentary shaping near-term sentiment more than any single earnings, product, or M&A event. Continuation likelihood over the next few weeks looks modestly positive but not decisive, since analyst reiterations tend to produce muted follow-through absent a fresh fundamental trigger. Informational only — not financial advice.
- Can a Spinoff Fix Johnson & Johnson’s Medtech Problem?Yahoo · 2026-10-13
- Cyclicals Lead Sectors In Tuesday Trading As Health Care TrailsBenzinga · 2026-10-13
- RBC Capital Reiterates Outperform on AbbVie, Maintains $280 Price TargetBenzinga · 2026-10-13
- Netflix, DocuSign And A Health Care Stock On CNBC’s ‘Final Trades’Benzinga · 2026-10-13
- AbbVie (ABBV) Could Be 44% Below Fair Value On Fresh Pipeline WinsYahoo · 2026-10-13
Any AI summary is an interpretation of public news, not advice or a price target.